Rare Diseases Update: Genetics and Targeted Treatment in HAE and CVID


Activity Overview

This activity, presented by Dr. Marc A. Riedl, highlights recently updated HAE clinical practice guidelines, treatment advances, and emerging therapies for HAE. Dr. Riedl discusses how to distinguish CVID from other immunodeficiencies as well as immunoglobulin replacement therapy and emerging targeted therapies for CVID. Learners will gain insight on optimizing individualized patient care and considerations for improving quality of life for patients with HAE and CVID.

0.50 CE Credit(s)
Expires: January 4, 2022

Target Audience

This educational activity is designed for allergy/immunology clinicians, including physicians, nurse practitioners, physician assistants, and nurses who manage patients with hereditary angioedema (HAE) and/or common variable immune deficiency (CVID).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Recognize the role of genetic and new diagnostic testing in the evaluation of patients with hereditary angioedema (HAE)
  • Evaluate the efficacy and safety of treatments that are indicated and under investigation for HAE
  • Identify appropriate genetic testing strategies for common variable immune deficiency (CVID) that may change management strategies
  • Describe the IgRT options indicated for the treatment of CVID

Activity Faculty

Riedl Photo 300 dpi (1)

Marc A. Riedl, MD, MS

Professor of Medicine
Clinical Director
, US HAEA Angioedema Center
Clinical Service Chief & Training Program Director 
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA